Status:
UNKNOWN
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer
Lead Sponsor:
Maidstone & Tunbridge Wells NHS Trust
Collaborating Sponsors:
University of Kent
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-85 years
Brief Summary
Gene expression, the transfer of the genetic code into cellular proteins is one of the most fundamental processes in living cells. This process is orchestrated by protein-based molecular machines, cal...
Detailed Description
Purpose and Design The primary aim of this project is to understand the significance of the newly discovered interaction between myosin VI (MVI) and the oestrogen receptor in breast cancer cells. The ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of early breast cancer
- Palpable tumour greater than 2cm
- Scheduled for primary surgical treatment
Exclusion
- Locally advanced breast cancer
- Metastatic breast cancer
- Significant co-morbidities (ASA 4 or above)
- Past history of breast cancer
Key Trial Info
Start Date :
May 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03430024
Start Date
May 5 2019
End Date
December 1 2020
Last Update
November 13 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maidstone and Tunbridge Wells NHS Trust
Maidstone, Kent, United Kingdom, ME16 9QQ